On anti-ischemic and anti-hypoxic activity of the novel compound of (Rs) 4-nytro-N-[1-phenyl-5-(diethylamino)penthyl]benzamid

Introduction. The recent studies demonstrated acute toxicity data and antiarrhythmic activity of a novel compound 4-Nytro-N-[1-Phenyl-5-(Diethylamino) Penthyl]Benzamid. These results allow us to suggest the presence of anti-ischemic and anti-hypoxic activities in the compound. Material and Methods. The experiments have been carried out in male rats by differential staining method of heart's necrotic and ischemic zones size dimension; asphyxiation and hyper carbonic hypoxia were set in mice. The inotropic activity of the compound was studied in rat's isolated hypoxic heart by Langendorf method. Results. The experiment in rats with acute myocardial infarction shows that preventive intravenous administration of 1,7 mg/kg (it corresponds with 5 % DL50 index for mice) L-glutamic compound of 4-Nytro-N-[1-Phenyl-5(Diethylamino) Penthyl] Benzamid (laboratory name LCT-H102) solution leads to heart's necrotic zone restriction. Isolated rat's heart perfusion by 10-5 M LCT-N102 solution demonstrates positive inotropic activity. The compound administered by the mentioned way, prolongs both bioelectric cardiac activity and life expectancy of mice with experimental acute asphyxiation and hyper carbonic hypoxia. Considering these results we can constitute with high probability that LCT-N102 anti-ischemic effect is a consequence of its anti-hypoxic activity as well as myocardial bioelectric process optimization.